Peer-influenced content. Sources you trust. No registration required. This is HCN.

Trending Topics:
DIET & NUTRITION PATIENT EDUCATION OBESITY/WEIGHT MANAGEMENT EXERCISE/TRAINING LEGAL MATTERS GUIDELINES/RECOMMENDATIONS

Articles related to PSYCHOPHARMACOLOGY

Psych Congress Network

Lumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

Psychiatry May 27th 2026

Tags: ANTIPSYCHOTICS DEPRESSION EVIDENCE REVIEW MENTAL HEALTH MOOD DISORDERS PHARMACOTHERAPY PSYCHOPHARMACOLOGY

Psychiatry Advisor

Clozapine, Amisulpride, Olanzapine, Risperidone Most Effective For Schizophrenia

A network meta-analysis of 24 antipsychotics across 78,193 patients with schizophrenia identified clozapine, amisulpride, olanzapine, and risperidone as most effective, with small-to-medium efficacy differences and notable variation in tolerability profiles.

Psychiatry April 29th 2026

Tags: ANTIPSYCHOTICS EVIDENCE REVIEW PERSONALIZED MEDICINE PSYCHOPHARMACOLOGY SCHIZOPHRENIA SIDE EFFECTS

Epoch Health

When Medicine Leads to More Medicine

Clinicians often are unaware that gabapentinoids can cause peripheral edema or even respiratory depression.

Clinical Pharmacology February 4th 2026

Tags: DRUG SAFETY & INTERACTIONS PRESCRIBING CASCADE PSYCHOPHARMACOLOGY

Psychiatrist.com

MAOI Antidepressants: A History Being Rewritten

The historical use of classic monoamine oxidase inhibitors (MAOIs) is overviewed, with consideration given to their efficacy and safety before discussing the importance of reassessing their place in current treatment algorithms.

Psychiatry January 21st 2026

Tags: ADVERSE EVENTS ANTIDEPRESSANTS DEPRESSION DRUG SAFETY & INTERACTIONS GUIDELINES/RECOMMENDATIONS PSYCHOPHARMACOLOGY

Psych Congress Network

Overview of Anticholinergic Medications

Anticholinergic medications require careful consideration of both peripheral and central effects, particularly in patients with existing cognitive impairments.

Family Medicine/General Practice December 11th 2024

Tags: COGNITIVE HEALTH/MEMORY DRUG SAFETY & INTERACTIONS GUIDELINES/RECOMMENDATIONS MOVEMENT DISORDERS PSYCHOPHARMACOLOGY

Topics

Sources

American Journal of Clinical Pathology (AJCP)
American Nurse Journal (ANJ)
Anesthesiology News
Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cardiology Advisor
Cleveland Clinic Journal of Medicine (CCJM)
Clinical Advisor
Conexiant
Consultant360
Cureus
Dermatology Advisor
Endocrinology Advisor
Gastroenterology Advisor
GoodRx for Healthcare Professionals
Healthgrades for Professionals
Hematology Advisor
JNP: The Journal for Nurse Practitioners
Journal of Invasive Cardiology (JIC)
Journal of the American College of Cardiology (JACC)
Journal of the National Cancer Institute (JNCI)
Mayo Clinic
MD Newsline
MDLinx
MedCentral
Medical News Today (MNT)
Medical Professionals Reference (MPR)
Neurology Advisor
Oncology News Central (ONC)
Ophthalmology Advisor
Pharmacy Practice News
Physician’s Weekly
POCN
Practical Neurology
Psychiatrist.com
Psychiatry Advisor
ReachMD
Renal & Urology News
The American Journal of Nursing (AJN)
UCLA Health
WebMD
Women’s Healthcare
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form